“Avatar,” a microfluidic organ-on-a-chip developed by the Wyss Institute (Harvard University), provides insights into health risks faced by astronauts (the effects of radiation and microgravity)

“Avatar,” a microfluidic organ-on-a-chip developed by the Wyss Institute (Harvard University), provides insights into health risks faced by astronauts (the effects of radiation and microgravity)

April 13, 2026 · 20 min

About this episode

The episode discusses breakthroughs in health technology, focusing on a microfluidic organ-on-a-chip developed by the Wyss Institute and a new Alzheimer’s treatment using viral vectors.

These sources highlight two major breakthroughs in health technology involving organ-on-a-chip systems and genetic engineering . The Harvard Wyss Institute has developed AVATAR , a microfluidic device using an astronaut's own cells to study the harmful effects of deep-space radiation and microgravity. This technology allows researchers to isolate specific physiological stressors without the confounding variables of a living subject's lifestyle. Simultaneously, a new Alzheimer’s treatment uses viral vectors to reprogram brain cells called astrocytes into efficient "cleaners" of toxic proteins. By equipping these cells with chimeric antigen receptors (CAR) , scientists have successfully cleared amyloid waste through a single injection. Together, these advancements represent a shift toward personalized, self-contained medical solutions for complex biological challenges.

More episodes of HealthTech Deep Dive

Explore listener stats, chart rankings, contacts and more on the HealthTech Deep Dive podcast page.